Affinity Asset Advisors LLC Has $22.24 Million Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Affinity Asset Advisors LLC increased its ownership in Centessa Pharmaceuticals by 41.1% during the first quarter, making it the firm's 10th largest position with approximately $22.24 million in holdings.
• Centessa Pharmaceuticals reported a loss of ($0.38) earnings per share for the last quarter, which was below analysts' expectations.
• Despite recent sell-offs by insiders, 82.01% of Centessa Pharmaceuticals' stock is held by institutional investors, reflecting strong institutional interest in the company.

Affinity Asset Advisors LLC lifted its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 41.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,546,662 shares of the company's stock after buying an additional 450,738 shares during the period. Centessa Pharmaceuticals makes up 2.1% of Affinity Asset Advisors LLC's portfolio, making the stock its 10th biggest position. Affinity Asset Advisors LLC owned 1.16% of Centessa Pharmaceuticals worth $22,241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd boosted its holdings in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in Centessa Pharmaceuticals in the first quarter valued at about $47,000. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Centessa Pharmaceuticals in the first quarter valued at about $147,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insider Buying and Selling

In other news, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total transaction of $126,744.06. Following the sale, the insider directly owned 208,163 shares in the company, valued at approximately $3,170,322.49. This represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the sale, the insider owned 122,279 shares in the company, valued at approximately $1,902,661.24. This represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock valued at $2,472,814 over the last quarter. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock traded up $0.23 on Friday, reaching $16.79. 632,847 shares of the company were exchanged, compared to its average volume of 1,036,740. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The company's 50-day moving average is $15.70 and its two-hundred day moving average is $14.47. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -9.38 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target for the company. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $40.00 target price on the stock. Truist Financial assumed coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 target price on the stock. Wall Street Zen downgraded Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $31.50.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.